Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Medshine Discovery Inc.

Qilu Pharmaceutical Co., Ltd.

Hubei Bio-pharmaceutical Industrial Technological Institute Inc.

Cisen Pharmaceutical Co., Ltd.

Humanwell Healthcare (group) Co., Ltd.

North China Pharmaceutical New Drug R&d Co., Ltd.

North China Pharmaceutical Company., Ltd.

Shanghai Jia Tan Pharmatech Co., Ltd.

Humanwell Healthcare Co., Ltd.

Zhaozhong Ding

Fei Sun

Ling Yang

Shuhui Chen

Yilong Zhou

Yinghu Hu

Zheng Wang

Rui Zhao

Hao Wu

Lifang Wu

Xiaobing Yan

Wei Luo

Wei Huang

Yong Wang

Feng Guo

Yong Xu

Lie Li

Long Zhang

Xile Liu

Lu Huang

Zhibo Zhang

Zhe Cai

Xuehai Wang

Zhigang Huang

Cailin Wang

Ronghua Tu

Wenjie Sun

Baoping Zhao

Hailiang Chen

Haiwen Wan

Yang Yue

Minghui Zhang

Chuanwen Fan

Dongdong Tang

Yingying Yang

Xinhua Lu

Yepeng Wang

Guanghua Lai

Jinqing Hu

Qingmei Zheng

Yidong Zhu

Guimin Dong

Pingfan Zhou

Renlong Gao

Baoling Duan

Gangli Gong

Shansong Zheng

Gang Li

The present invention relates to crystalline form A of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)-benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), a method for preparing the crystalline form A, and the use thereof. 

Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine for inhibiting toll-like receptor activity

The present invention relates to a maleate salt of a compound represented by formula I, a method for preparing the salt, a pharmaceutical composition containing the salt, and the use of the salt. The present invention also relates to crystalline forms C, D and E of the maleate salt of the compound represented by formula I, methods for preparing the crystalline forms, crystalline compositions and pharmaceutical compositions containing the crystalline forms, and uses thereof. 

TLR7 agonist maleate salt, crystalline forms C, D and E thereof, preparation methods and uses of maleate salt and crystalline forms

The present invention relates to a trifluoroacetate salt of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), crystalline form B of the trifluoroacetate salt, methods for preparing the trifluoroacetate salt and crystalline form B, and uses of the trifluoroacetate salt and crystalline form B. 

TLR7 agonist trifluoroacetate salt and crystalline form B thereof, preparation methods and uses

The present invention relates to a 7-(thiazol-5-yl)pyrrolopyrimidine compound as a TLR7 agonist, and particularly relates to a compound shown in formula (I), pharmaceutically acceptable salt and preparation method thereof, a pharmaceutical composition containing such a compound, and usage thereof in preparing an antiviral drug. 

7-(thiazol-5-yl) pyrrolopyrimidine compound as TLR7 agonist

The present invention relates to a method for preparing a pyrrolo[3,2-d]pyrimidine compound (the compound represented by formula I), and corresponding intermediates. 

Method for preparing pyrrolo[3,2-D]pyrimidine compound, and intermediates thereof

The present invention relates to a pyrrolopyrimidine compound as TLR7 agonist, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition containing such compounds and use thereof for manufacturing a medicament against viral infection. 

Pyrrolopyrimidine compounds used as TLR7 agonist

Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D] pyrimidin-4-amine, preparation process and use thereof

A preparation method for a high-purity benzoxazoleoxazine ketone compound, a crystal form thereof, and an intermediate compound for preparing a compound of formula (I), and a preparation method therefor. 

Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof

Disclosed is a spirocyclic aryl phosphorus oxide or sulfide as an ALK inhibitor, particularly, a compound represented by formula (I) as an ALK inhibitor or pharmaceutically acceptable salt thereof. 

Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide

Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X is selected from a 3-9 membered carbon ring or a ring which is formed by 3-9 membered carbocyclic ring fused with benzo ring, and a 4-10 membered heterocyclic ring or a ring which is formed by 4-10 membered heterocyclic ring fused with benzo ring; Y and Z are independently selected from 4-9 membered saturated heterocyclic rings respectively; Rare independently selected from H, F, Cl, Br, I, CN, OH, SH, NH, CHO, COOH respectively, or selected from the group, optionally substituted by R, consisting of Calkyl, Cheteroalkyl, Ccyclohydrocarbyl, Cheterocyclohydrocarbyl, Calkyl substituted by Ccyclohydrocarbyl or Cheterocyclohydrocarbyl, and Cheteroalkyl substituted by Ccyclohydrocarbyl or Cheterocyclohydrocarbyl. The compound can be used as an anticoagulant for treating and preventing thrombotic disorders, and can meet the real needs of selectivity and a potent inhibitor for coagulation Xa. 

Hydrazine compound as blood coagulation factor Xa inhibitor

Disclosed are a method for preparing a series of novel pyridine derivatives and a use thereof. Such derivatives can be used in the treatment of related diseases caused by mycobacteria, in particular diseases caused by pathogenic mycobacteria, such asand

Pyridine derivatives and anti-mycobacterial use thereof

Disclosed is a series of analogs of 4H-pyrazolo[1,5-&#x3b1;]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.

Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors

Growing community of inventors

Shanghai, China

Zhaozhong Ding